Moderna amends credit agreement, lowers loan rates and extends maturities
Moderna, Inc. (NASDAQ:MRNA) recently amended its credit agreement with Ares Capital Corporation, lowering loan rates and extending maturities. Effective immediately, the interest rate margins for initial term loans and delayed draw term loans have been reduced by 0.75 percentage points. For forward-looking term rate loans, the interest rate drops from 5.50% to 4.75% per annum, while loans based on the base rate see a reduction from 4.50% to 3.75% per annum.
The company's total debt stands at $4.2 billion, with a current ratio of 3.62, indicating strong liquidity. Additionally, the maturity date for the affected loans has been extended by one year, from November 24, 2030, to November 24, 2031. The availability period for delayed draw term loan commitments has also been extended for both portions: the first $400 million from November 24, 2027, to November 24, 2029, and the remaining $500 million from November 24, 2028, to November 24, 2029.
These changes come as Moderna continues to experience strong sales performance and a more optimistic outlook for 2026.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.